Last reviewed · How we verify
NCT03795506
TLA in Children With Moderate to Severe Atopic Eczema (TLA4AE)
NA trial testing Nocturnal Temperature controlled Laminar Airflow (TLA) Treatment in Atopic Dermatitis Eczema in 96 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | Imperial College London |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 96 |
| Start date | 8 July 2019 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 May 2025 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Nocturnal Temperature controlled Laminar Airflow (TLA) Treatment
- Placebo TLA Device
Conditions studied
- Atopic Dermatitis Eczema — all drugs for Atopic Dermatitis Eczema →
Sponsor
Imperial College London
Who can join
Adults 4 to 16, any sex, with Atopic Dermatitis Eczema. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single centre randomised, placebo-controlled phase 2 study in which 96 children age 4 to 16 years with moderate to severe, longstanding allergic eczema will be enrolled.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03795506
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Atopic Dermatitis Eczema
Currently open trials in the same condition.
- NCT06855745 — Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD. · Phase 2 · recruiting
- NCT06850311 — Herbal Ointment in Treating Atopic Dermatitis Topically · Phase 2, PHASE3 · recruiting
- NCT06024499 — Phase 2 Trial of HY209gel in Atopic Dermatitis Patients · Phase 2 · active not recruiting
- NCT06004986 — DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema · Phase 4 · recruiting
- NCT05316805 — China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project · recruiting
Other Imperial College London trials
Trials by the same sponsor.
- NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH · NA · not yet recruiting
- NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants · Phase 1 · not yet recruiting
- NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing · NA · not yet recruiting
- NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy · Phase 2 · not yet recruiting
- NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03795506 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Imperial College London
- Last refreshed: 8 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03795506.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing